コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ce of inflammation, despite continued use of maintenance therapy.
2 rapamycin+mycophenolate mofetil treatment as maintenance therapy.
3 ts to lenalidomide maintenance therapy or no maintenance therapy.
4 Responding patients could receive maintenance therapy.
5 important to establish the potential role of maintenance therapy.
6 ant treatment must include the need for such maintenance therapy.
7 partial response (PR) with R-FCM were given maintenance therapy.
8 cycles, followed by pomalidomide-prednisone maintenance therapy.
9 dependent HIV-infected patients on methadone maintenance therapy.
10 ol, independent of baseline severity and the maintenance therapy.
11 RIT consolidation and/or extended rituximab maintenance therapy.
12 ction, and sirolimus with or without CTLA4Ig maintenance therapy.
13 (153 patients) or MP (154 patients) without maintenance therapy.
14 mportant in assessing the clinical impact of maintenance therapy.
15 rs associated with compliance to periodontal maintenance therapy.
16 nued ipilimumab or placebo every 12 weeks as maintenance therapy.
17 f response and remission with ustekinumab as maintenance therapy.
18 none of the drugs evaluated is approved for maintenance therapy.
19 Eight patients started maintenance therapy.
20 nd concomitant treatments, including aspirin maintenance therapy.
21 ng the incidence of treatment failure during maintenance therapy.
22 obulin induction and steroid-free tacrolimus maintenance therapy.
23 ients, recent trials have shown benefit with maintenance therapy.
24 lar remitters received 2 years of risk-based maintenance therapy.
25 omplete or partial) response to induction or maintenance therapy.
26 the efficacy of tofacitinib as induction and maintenance therapy.
27 h in the first hours of treatment and during maintenance therapy.
28 nd large, including new MIs occurring during maintenance therapy.
29 n agent, tacrolimus and mycophenolic acid as maintenance therapy.
30 more cycles, each given 3 months apart, for maintenance therapy.
31 0 control patients and in 58 of 88 receiving maintenance therapy.
32 ppression of HCV RNA by >or=4 log(10) during maintenance therapy.
33 nosis, after three cycles of RVD, and before maintenance therapy.
34 file, may be a promising candidate agent for maintenance therapy.
35 acrolimums and a steroid taper were used for maintenance therapy.
36 s both for acute induction and for long-term maintenance therapy.
37 HAART, and responses were sustained on IL-12 maintenance therapy.
38 onic acid, presented for routine periodontal maintenance therapy.
39 hymocyte globulin induction with triple drug maintenance therapy.
40 venox and high dose tacrolimus and sirolimus maintenance therapy.
41 al nervous system prophylaxis while omitting maintenance therapy.
42 (1344 patient-months for the cohort) during maintenance therapy.
43 e taking inhaled glucocorticoid-based triple maintenance therapy.
44 erapy to the primary tumour site followed by maintenance therapy.
45 progress as part of induction, salvage, and maintenance therapy.
46 he treatment of periodontitis or periodontal maintenance therapy.
47 ared with gemcitabine plus erlotinib used as maintenance therapy.
48 phine (BUP) are widely prescribed for opiate maintenance therapy.
49 third, suggesting a role as postchemotherapy maintenance therapy.
50 exed alone followed by indefinite pemetrexed maintenance therapy.
51 etastatic disease, especially when used as a maintenance therapy.
52 tekinumab was also evaluated as subcutaneous maintenance therapy.
53 t when added to inhaled corticosteroid (ICS) maintenance therapy.
54 , and employ the use of aggressive long-term maintenance therapy.
55 a) in patients receiving regular periodontal maintenance therapy.
56 ued with up to 12 further 3-weekly cycles of maintenance therapy.
57 d on lasers treating inflamed pockets during maintenance therapy.
58 years and continued to receive ipilimumab as maintenance therapy.
59 th normokalemia maintained during 12 days of maintenance therapy.
60 munotherapy and in some cases during ongoing maintenance therapy.
61 terruptions, booster therapies and induction-maintenance therapies.
62 level of improvement during continuation and maintenance therapies.
63 ered after the six cycles of chemotherapy as maintenance therapy (15 mg/kg once every 3 weeks) until
66 sulting in a significant shorter duration of maintenance therapy (5 vs 17 months in MPR-R), irrespect
69 nd second primary malignancies, lenalidomide maintenance therapy after ASCT significantly improved ti
73 The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line
74 for both skin and lung disease, alone or for maintenance therapy after cyclophosphamide induction.
75 egy of monoimmunotherapy is not effective as maintenance therapy after front-line treatment of a favo
76 atic patients early, and providing long-term maintenance therapy after patients experience a first re
80 EX and IVIG both have high response rates as maintenance therapies and are reasonable therapeutic opt
82 s between the end of induction and week 7 of maintenance therapy and were treated with chemotherapy a
83 n were assigned to delayed consolidation and maintenance therapy, and allo-HSCT was scheduled in pati
84 standing of EoE progression and the need for maintenance therapy, and continue development of diagnos
85 and salvage treatments, what is the role of maintenance therapy, and is there any role for stem cell
86 ired the presence of all three agents during maintenance therapy, and resulted in graft acceptance fo
87 nced lung cancer who progressed on erlotinib maintenance therapy, and subsequently had leptomeningeal
88 s, optimal treatment end points, the role of maintenance therapy, and treatment of refractory EoE.
89 y were advised to continue this treatment as maintenance therapy, and women who required both antipsy
90 -, or caregiver-administered oral 6MP during maintenance therapy; and (4) completion of at least 6 mo
93 ion of the optimal duration and frequency of maintenance therapy as well as development of targeted t
94 s a novel tocolytic agent for both acute and maintenance therapy, as it inhibits both myometrial cont
95 evaluated and resampled and received regular maintenance therapy at 3, 6, and 12 months after treatme
97 dependent HIV-infected patients on methadone maintenance therapy at a drug abuse outpatient center.
98 ; and (4) completion of at least 6 months of maintenance therapy at the time of study enrollment.
99 ceived induction, consolidation, and interim maintenance therapy before they began delayed intensific
101 a bortezomib-based induction and bortezomib maintenance therapy compared with conventional induction
102 high-dose cytarabine and anthracycline, and maintenance therapy comprising ATRA, oral methotrexate,
103 treatment allocation, and bisphosphonate and maintenance therapy continued at least until disease pro
109 receiving rATG induction and steroid-sparing maintenance therapy evaluates the effect of small change
111 a total of four administrations, followed by maintenance therapy every 12 weeks in patients who remai
112 n therapy received obinutuzumab or rituximab maintenance therapy every 2 months for up to 2 years.
113 receive ipilimumab at 10 mg/kg or placebo as maintenance therapy every 3 months until disease progres
119 efitinib can be administered with FHX and as maintenance therapy for at least 2 years, demonstrating
120 posure to oral 6-mercaptopurine (6MP) during maintenance therapy for childhood acute lymphoblastic le
121 control (MPC) strategy is presented in which maintenance therapy for childhood ALL is personalized us
122 recommendations regarding 6-MP intake during maintenance therapy for childhood ALL should aim to simp
125 Local consolidative therapy with or without maintenance therapy for patients with three or fewer met
127 ith esomeprazole on-demand versus continuous maintenance therapy for symptom control in patients with
133 eatment of certain hematologic malignancies, maintenance therapy has only recently become a treatment
137 to examine outcomes associated with hormonal maintenance therapy (HMT) compared with routine observat
139 olerated as add-on therapy to ICS with other maintenance therapies in children with severe symptomati
140 corticosteroids (ICSs) with or without other maintenance therapies in patients with moderate or sever
141 response were documented after 12 months of maintenance therapy in 87%, 72%, and 22% of patients, re
142 concentrated platelets after a loading dose/maintenance therapy in a time-dependent manner under in
143 nd well tolerated when added to at least ICS maintenance therapy in adolescent patients with moderate
144 sion resulted in long-term remission without maintenance therapy in approximately 15% of patients.
145 phase 2 clinical trial evaluating rituximab maintenance therapy in chronic lymphocytic leukemia (CLL
147 d studies evaluated infliximab induction and maintenance therapy in moderately to severely active ulc
148 y being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment
149 exploring the benefit of adding androgens to maintenance therapy in patients 60 years of age or older
150 t provides evidence that using infliximab as maintenance therapy in patients in glucocorticoid-induce
151 rrent data and perspectives of consolidation/maintenance therapy in patients with advanced NSCLC.
152 doxorubicin, followed by single-agent TH-302 maintenance therapy in patients with first-line advanced
153 red lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed mul
154 s the efficacy and safety of lenalidomide as maintenance therapy in patients with previously treated
157 ts who received thalidomide in induction and maintenance therapy in the Total Therapy (TT) 2 trial (i
160 ble to undergo this procedure and subsequent maintenance therapy in those failing to achieve a comple
161 thiopurine or methotrexate), or vedolizumab maintenance therapy in those who successfully achieve sy
162 is factor-alpha (TNFalpha), was evaluated as maintenance therapy in TNFalpha antagonist-naive adults
163 which included treatment and >or=15 years of maintenance therapy, in a private practice in Yamagata,
164 d caution against the use of sirolimus-based maintenance therapy, in HIV-positive individuals undergo
169 ulto MM-015 trials suggest that lenalidomide maintenance therapy is associated with a higher incidenc
172 dding to the effects of standard treatments, maintenance therapy is likely to help incrementally exte
173 f plasmapheresis (PLEX) vs immunoglobulin as maintenance therapy is unclear for this childhood diseas
176 divided by the planned protocol dose during maintenance therapy; its association with genotype was e
177 nalysis suggests no effect of stable lithium maintenance therapy (lithium levels in therapeutic range
178 nt with improved results; posttransplant TKI maintenance therapy may also provide survival benefit.
181 with opioid dependence undergoing methadone maintenance therapy (MMT) in a randomized, double-blind,
182 ioid-dependent patients undergoing methadone-maintenance-therapy (MMT) and healthy controls (HCs) wer
183 or more of prior GC exposure, not receiving maintenance therapy (n = 15); (2) currently receiving bu
184 ion model analysis demonstrated that steroid maintenance therapy (odds ratio: 8.3, P=0.003) and induc
188 We aimed to assess the effect of lithium maintenance therapy on estimated glomerular filtration r
189 an 40 years, the long-term effect of lithium maintenance therapy on renal function has been debated.
190 differences in outcomes of those who reached maintenance therapy on time compared with those who were
191 l trials have reported that consolidation or maintenance therapy or both improves progression free su
192 Completed trials evaluating consolidation or maintenance therapy or both in patients with advanced NS
195 ither peginterferon alfa-2a (90 microg/week) maintenance therapy or no treatment (control) for 3.5 ye
196 ment and its timing and is there any role of maintenance therapy or stem cell transplantation in this
197 umab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pe
198 y assigned 240 patients to receive rituximab maintenance therapy or to undergo observation after auto
199 therapy concurrently with radiotherapy or as maintenance therapy, or both, affected clinical outcome.
201 investigate association between peri-implant maintenance therapy (PIMT) and the frequency of peri-imp
202 rein at assessing the impact of peri-implant maintenance therapy (PIMT) on the prevention of peri-imp
204 iodontitis and tooth loss during periodontal maintenance therapy (PMT) programs have not previously b
205 lamed periodontal pockets during periodontal maintenance therapy (PMT), but evidence for efficacy fro
207 lantation, though similar indications in the maintenance therapy population have been described.
208 sible after randomisation, followed by daily maintenance therapy (prasugrel 10 mg or clopidogrel 75 m
209 herapy and 3.7 mug/mL at steady-state during maintenance therapy produced optimal outcomes in patient
210 redictable risk variables of two periodontal maintenance therapy programs over a 12-month period.
211 Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progres
212 III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progress
213 TERPRETATION: Lenalidomide is an efficacious maintenance therapy reducing the relative risk of progre
216 eive this therapy in their homes; therefore, maintenance therapy regimens, as well as the development
217 e time between end of induction and start of maintenance therapy resulted in inferior EFS (hazard rat
218 e 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progr
221 respectively; yet, current data suggest that maintenance therapy should continue at least until progr
222 , and lenalidomide, followed by lenalidomide maintenance therapy, showed promising results without se
225 gression-free survival noted with pemetrexed maintenance therapy, such treatment is an option for pat
226 ently underwent a random allocation (1:1) to maintenance therapy (thalidomide plus dexamethasone) or
228 lues from the screening and day-0 visits) to maintenance therapy (the average of values from the week
229 In these subjects receiving periodontal maintenance therapy, there was a trend for better period
230 s at relapse reduce the potential benefit of maintenance therapy; this should only be advocated in th
232 daily/maintenance treatment for 5 to 7 days (maintenance therapy: ticagrelor 90 mg BID plus aspirin 8
234 -week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progressi
235 izumab to standard chemotherapy, followed by maintenance therapy until progression, improved the medi
236 kly paclitaxel (70 mg/m(2), 3 of 4 weeks) as maintenance therapy until unacceptable toxicity or disea
237 e patients were randomly assigned to receive maintenance therapy using BIBF 1120 250 mg or placebo, t
240 single infusion of rituximab (375 mg/m2) as maintenance therapy was administered whenever the freque
243 t week 54 without dose adjustment when their maintenance therapy was given every 8 weeks rather than
244 ial demonstrated that low-dose peginterferon maintenance therapy was ineffective in preventing clinic
245 cohort of 51 subjects receiving periodontal maintenance therapy was recruited from two dental clinic
249 s cladribine (9 mg/m(2) per day) followed by maintenance therapy, was administered to 27 patients (me
253 es 22 patients receiving regular periodontal maintenance therapy who had one or more periodontal site
254 ri eradication triple therapy and 8 weeks of maintenance therapy with a proton pump inhibitor; and 4)
256 apy was discontinued in patients on combined maintenance therapy with antimetabolites and identified
257 ese preliminary data suggest that simplified maintenance therapy with atazanavir-ritonavir alone may
259 mmunosuppression for all recipients included maintenance therapy with belatacept and mycophenolate mo
260 received prednisone 40 mg/d for 2 weeks and maintenance therapy with budesonide/formoterol 400/12 mu
261 ate-to-severe Crohn's disease, induction and maintenance therapy with certolizumab pegol was associat
262 tients were randomly assigned to one year of maintenance therapy with either tretinoin alone or in co
266 e severely symptomatic disease and value for maintenance therapy with limited potential side effects,
267 tion therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA.
269 ith cidofovir, reduced immunosuppression and maintenance therapy with no agents other than SRL (C0=10
270 lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patie
271 Conclusion This study demonstrates that maintenance therapy with norethandrolone significantly i
272 ed trial comparing thalidomide-prednisone as maintenance therapy with observation in 332 patients who
274 l response were randomly assigned to receive maintenance therapy with one infusion of rituximab every
275 rhosis (HALT-C) Trial showed that 4 years of maintenance therapy with pegylated interferon (peginterf
276 al randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (I
278 zed phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients wit
284 response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, e
285 oved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.
286 2.9; 95% confidence interval, 1.3-6.7), and maintenance therapy with rituximab should be considered
287 Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improve
288 n each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 week
291 All were treated with RATG induction and maintenance therapy with tacrolimus, mycophenolate mofet
292 Taken together, these results suggest that maintenance therapy with tacrolimus/MMF is more favorabl
293 using lymphocyte depletion as induction and maintenance therapy with target of rapamycin inhibitors.
296 on therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10
298 control, and 67.3% were randomly assigned to maintenance therapy, with 125 and 128 receiving single-a
299 4 received low dose tacrolimus and sirolimus maintenance therapy, with splenectomy, anti-CD20 and dai
300 ex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。